Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cogent BiosciencesCOGT -0.38%30 Debt-to-Equity is 0.39 as of Mar. 2026, which is 457% above its 10-year median of 0.07. GuruFocus rates COGT with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 966 Biotechnology companies, Cogent Biosciences ranks worse than 68.94% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cogent Biosciences's Debt-to-Equity or its related term are showing as below:
COGT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.07 Max: 0.39
Current: 0.39
During the past 11 years, the highest Debt-to-Equity Ratio of Cogent Biosciences was 0.39. The lowest was 0.02. And the median was 0.07.
COGT's Debt-to-Equity is ranked worse than 68.94% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs COGT: 0.39
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cogent Biosciences Debt-to-Equity Related Terms
Cogent Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cogent Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COGT vs SRRK, CGON, LGND: Debt-to-Equity Comparison
For the Biotechnology subindustry, Cogent Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (COGT) has a Debt-to-Equity of 0.39 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cogent Biosciences and its competitors. This is 457% above median its historical median of 0.07. Over the past decade, Cogent Biosciences' Debt-to-Equity has ranged from 0.02 to 0.39. According to the industry distribution chart, Cogent Biosciences ranks #666 out of 966 companies in the Biotechnology industry, placing it in the top 68.9%.
Is Cogent Biosciences' Debt-to-Equity too high?
Cogent Biosciences' current Debt-to-Equity of 0.39 is 457% above median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.39. The Biotechnology industry median Debt-to-Equity is 0.16. Cogent Biosciences' value of 0.39 is 143.8% above this industry median. Based on the distribution chart, Cogent Biosciences ranks #666 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cogent Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Debt-to-Equity compare to SRRK and CGON?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #666 out of 966 companies for Debt-to-Equity. This places Cogent Biosciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Cogent Biosciences' value of 0.39 is 143.8% above this benchmark. Historically, Cogent Biosciences' own Debt-to-Equity has ranged from 0.02 to 0.39 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.16, Cogent Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogent Biosciences's current Debt-to-Equity of 0.39 is 143.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cogent Biosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogent Biosciences's current Debt-to-Equity is 0.39, which is 457% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Debt-to-Equity of 0.39. The current Debt-to-Equity is 0.39, which is 457% above median its 10-year median of 0.07 and 143.8% above the Biotechnology industry median of 0.16. Cogent Biosciences' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Debt-to-Equity is 0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
30GF Score
Get the complete analysis for COGT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
